Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia

References

• MariJJLeitãoRJThe epidemiology of schizophreniaRev Bras Psiquiatr.200022Suppl I1517 Portuguese.
   Google Scholar
• RegierDABoydJHBurkeJDOne-month prevalence of mental disorders in the United StatesArch Gen Psychiatry198845119779863263101
   PubMed Web of Science ®Google Scholar
• RegierDAFarmerMERaeDSOne-month prevalence of mental disorders in the United States and sociodemographic characteristics: The Epidemiologic Catchment Area studyActa Psychiatr Scand199388135478372694
   PubMed Web of Science ®Google Scholar
• KaneJMPharmacologic treatment of schizophreniaBiol Psychiatry199946101396140810578454
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDLacroJPDolderCRA prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophreniaJ Clin Psychiatry20066771114112316889456
   PubMed Web of Science ®Google Scholar
• ByerlyMJNakoneznyPALescouflairEAntipsychotic medication adherence in schizophreniaPsychiatr Clin North Am200730343745217720031
   PubMed Web of Science ®Google Scholar
• KaneJMTreatment adherence and long-term outcomesCNS Spectrums20071210 Suppl 17212617934386
   PubMed Web of Science ®Google Scholar
• LacroJPDunnLBDolderCRLeckbandSGJesteDVPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry2002631089290912416599
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• PerkinsDOGuHWeidenPJPredictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter studyJ Clin Psychiatry200869110611318312044
   PubMed Web of Science ®Google Scholar
• RosaMAMarcolinMAElkisHEvaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophreniaRev Bras Psiquiatr2005275511178184 Portuguese.16224604
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv200455888689115292538
   PubMed Web of Science ®Google Scholar
• KnoxEDStimmelGLClinical review of a long-acting, injectable formulation of risperidoneClin Ther200426121994200215823763
   PubMed Web of Science ®Google Scholar
• LawMRSoumeraiSBRoss-DegnanDAdamsASA longitudinal study of medication nonadherence and hospitalization risk in schizophreniaJ Clin Psychiatry2008691475318312037
   PubMed Web of Science ®Google Scholar
• MasandPSNarasimhanMImproving adherence to antipsychotic pharmacotherapyCurr Clin Pharmacol200611475618666377
   PubMedGoogle Scholar
• RobinsonDWoernerMGAlvirJMPredictors of relapse following response from a first episode of schizophrenia or schizoaffective disorderArch Gen Psychiatry199956324124710078501
   PubMed Web of Science ®Google Scholar
• SvarstadBLShiremanTISweeneyJKUsing drug claims data to assess the relationship of medication adherence with hospitalization and costsPsychiatr Serv200152680581111376229
   PubMed Web of Science ®Google Scholar
• WeidenPJOlfsonMCost of relapse in schizophreniaSchizophr Bull19952134194297481573
   PubMed Web of Science ®Google Scholar
• DaltioCSMariJDJFerrazMBDirect medical costs associated with schizophrenia relapses in health care services in the city of São PauloRev Saúde Pública20114511423 Portuguese.
   Web of Science ®Google Scholar
• LeitãoRJFerrazMBChavesACMariJJCost of schizophrenia: direct costs and use of resources in the State of São PauloSchizophrenia2006402304309
   Google Scholar
• CsernanskyJGMahmoudRBrennerRA comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophreniaN Engl J Med20023461162211777998
   PubMed Web of Science ®Google Scholar
• WyattRJNeuroleptics and the natural course of schizophreniaSchizophr Bull19911723253511679255
   PubMed Web of Science ®Google Scholar
• DavisJMChenNGlickIDA meta-analysis of the efficacy of second-generation antipsychoticsArch Gen Psychiatry200360655356412796218
   PubMed Web of Science ®Google Scholar
• LeuchtSPitschel-WalzGAbrahamDKisslingWEfficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trialsSchizophr Res199935151689988841
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• EerdekensMVan HoveIRemmerieBMannaertEPharmacokinetics and tolerability of long-acting risperidone in schizophreniaSchizophr Res20047019110015246468
   PubMed Web of Science ®Google Scholar
• EreshefskyLMascarenasCAComparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamicsJ Clin Psychiatry200364Suppl 16182314680415
   PubMed Web of Science ®Google Scholar
• ChuePEerdekensMAugustynsIComparative efficacy and safety of long-acting risperidone and risperidone oral tabletsEur Neuro Psychopharmacol2005151111117
   PubMed Web of Science ®Google Scholar
• FleischhackerWWEerdekensMKarcherKTreatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychoticJ Clin Psychiatry200364101250125714658976
   PubMed Web of Science ®Google Scholar
• KaneJMEerdekensMLindenmayerJ-PLong-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychoticAm J Psychiatry200316061125113212777271
   PubMed Web of Science ®Google Scholar
• MöllerH-JLong-acting injectable risperidone for the treatment of schizophrenia: clinical perspectivesDrugs200767111541156617661527
   PubMed Web of Science ®Google Scholar
• NasrallahHDuchesneIMehnertAJanagapCEerdekensMHealth-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidoneJ Clin Psychiatry200465453153615119916
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for PsychopharmacologyRockville, MDUS Department of Health, Education, and Welfare1976
   Google Scholar
• MorosiniPLMaglianoLBrambillaLUgoliniSPioliRDevelopment, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioningActa Psychiatr Scand2000101432332910782554
   PubMed Web of Science ®Google Scholar
• AwadAGSubjective response to neuroleptics in schizophreniaSchizophr Bull19931936096187901897
   PubMed Web of Science ®Google Scholar
• ChouinardGMargoleseHCManual for the Extrapyramidal Symptom Rating Scale (ESRS)Schizophr Res2005762–324726515949657
   PubMed Web of Science ®Google Scholar
• LindenmayerJ-PKhanAEerdekensMVan HoveIKushnerSLong-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorderEur Neuro Psychopharmacol2007172138144
   PubMed Web of Science ®Google Scholar
• LloydKLatifMASimpsonSShresthaKLSwitching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcomeHum Psychopharmacol201025324325220373476
   PubMed Web of Science ®Google Scholar
• TurnerMEerdekensEJackoMEerdekensMLong-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychoticsInt Clin Psychopharmacol200419424115201572
   PubMed Web of Science ®Google Scholar
• Van OsJBossieCALasserRAImprovements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidoneInt Clin Psychopharmacol200419422923215201570
   PubMed Web of Science ®Google Scholar
• LasserRABossieCAGharabawiGMKaneJMRemission in schizophrenia: results from a 1-year study of long-acting risperidone injectionSchizophr Res2005772–321522715908183
   PubMed Web of Science ®Google Scholar
• MartinJLRPérezVSacristánMMeta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophreniaEur Psychiatry2006211112016380237
   PubMed Web of Science ®Google Scholar